BREVICON 21-DAY
LOE ApproachingNDAORAL-21TABLET
Approved
Dec 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BREVICON 21-DAY is an oral contraceptive tablet approved in 1974 containing a combination of hormonal agents for prevention of pregnancy. The product is a small-molecule oral contraceptive indicated for women seeking reliable birth control. It represents a mature, established therapeutic option in the contraceptive market.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%) suggests diminishing brand team resources and shift toward generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BREVICON 21-DAY offers limited growth opportunities as the product approaches loss of exclusivity with no linked job openings currently active. Roles are primarily focused on brand defense, generic transition planning, and compliance rather than market expansion or innovation.
Brand ManagerProduct Manager
Worked on BREVICON 21-DAY at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.